30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.
The results from this usability and acceptability analysis suggest that completing this brief battery of cognitive tests via a telephone call is both acceptable and feasible in a midlife-to-older adult population in the United Kingdom, living at risk for Alzheimer's disease. 4 key findings →
Participants: 68 Evidence: high
Full summary, score breakdown and related studies → Original source
The Mobile Health (mHealth) Intervention for Dementia Prevention through lifestyle Optimisation (MIND-PRO) study addresses the increasing prevalence of dementia among populations with lower socio-economic status (SES) and/or a migration background. 1 key finding →
Design: open-label trial Participants: 692 Evidence: high
Full summary, score breakdown and related studies → Original source
A rapidly aging world population is fueling a concomitant increase in Alzheimer's disease (AD) and related dementias (ADRD). 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
These data show the associations between dementia risk factors and cognition and attest to the excellent feasibility of the PROTECT Norge cohort, with over 3000 participants included over a period of 2 years and accessibility for people with early cognitive impairment. 2 key findings →
Participants: 3,214 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Older adults' between-person levels of daily MVPA and steps were associated with better mean cognitive performance and lower variability across cognitive measures. 5 key findings →
Design: cross-sectional Participants: 1,269 Evidence: low
Full summary, score breakdown and related studies → Original source
This randomized, observer-blind, controlled trial examined the efficacy and safety of the traditional Chinese herbal medicine Yi-Gan San (YGS, Yokukan-San in Japanese) in the improvement of behavioral and psychological symptoms of dementia (BPSD) and activities of daily living (ADL). 4 key findings →
Participants: 27 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer's disease is characterized by a slow, progressive decline in cognitive function and behaviour. 4 key findings →
Participants: 42 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The aim of this observational study was to evaluate whether the treatment of VRF is associated with a slower cognitive decline in patients who have AD without cerebrovascular disease (CVD). 4 key findings →
Participants: 72 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Guidelines recommend screening stroke-survivors for cognitive impairments. 4 key findings →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Because of the aging population and a rise in the number of stroke survivors, the prevalence of post-stroke cognitive impairment (PSCI) is increasing. 4 key findings →
Design: cohort study Participants: 280 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Public Psychiatric Hospital Rekem, Belgium. 4 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Cognitive dysfunction, including dementia and delirium, is prevalent in geriatric emergency department (ED) patients, but often remains undetected. 4 key findings →
Design: cohort study Participants: 163 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Cognitive assessments after stroke are typically short form tests developed for dementia that generates pass/fail classifications (e.g. the MoCA). 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Delirium is a profound neuropsychiatric disturbance precipitated by acute illness. 4 key findings →
Design: longitudinal study Participants: 465 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Patients with Alzheimer's Disease (AD) exhibit decreased retinal blood flow and vessel density (VD). 4 key findings →
Design: case-control study Participants: 16 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We recruited 825 individuals from the CHARLS sample and 766 subjects from hospitals in six provinces and cities in China. 4 key findings →
Design: longitudinal study Participants: 825 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
There is evidence that physical activity (PA) is of cognitive benefit to the ageing brain, but little is known on the effect in patients with Alzheimer's disease (AD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cognitive impairment is one of the earliest, most common, and most disabling non-motor symptoms in Parkinson's disease (PD). 4 key findings →
Design: cohort study Participants: 360 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The Neuropathology Task Force of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) has developed a practical and standardized neuropathology protocol for the postmortem assessment of dementia and control subjects. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
These findings provide support for both the feasibility and validity of C3 and computerized cognitive outcomes more generally in AD secondary prevention trials. 3 key findings →
Design: cross-sectional Participants: 4,486 Evidence: low
Full summary, score breakdown and related studies → Original source
Mean scaled scores in this longitudinal study were evaluated with repeated measures analysis of variance. 4 key findings →
Design: longitudinal study Participants: 14 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The data of 1734 participants (1158 with AD, 105 with DLB, 46 with VaD, and 425 with CN) were analyzed. 4 key findings →
Design: cross-sectional Participants: 1,734 Evidence: low
Full summary, score breakdown and related studies → Original source
We sought to develop and evaluate a composite memory score from the neuropsychological battery used in the Alzheimer's Disease (AD) Neuroimaging Initiative (ADNI). 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In mostly small single-center studies, Alzheimer's disease (AD) is associated with characteristic and progressive reductions in fluorodeoxyglucose positron emission tomography (PET) measurements of the regional cerebral metabolic rate for glucose (CMRgl). 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
One hundred and twenty-six patients diagnosed with Alzheimer-type dementia were selected from among 200 consecutive outpatients evaluated for suspected dementia from 1980 to 1982. 4 key findings →
Design: cohort study Participants: 126 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events